X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used by the company to focus on its FREE001, a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: FREE001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LongeVC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 14, 2023
Details:
The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory programs. Program FREE001 is a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: FREE001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MBX Capital
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Financing August 23, 2022
Details:
The company will use the net proceeds to focus on its FREE001, a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: FREE001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MBX Capital
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Financing August 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
